Citadel Advisors
ALLO icon

Citadel Advisors’s Allogene Therapeutics ALLO Stock Holding History

Citadel Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.6M Sell
6,793,620
-5,317,800
-44% -$10.7M ﹤0.01% 2564
2025
Q4 		$16.6M Sell
12,111,420
-1,860,137
-13% -$2.45M ﹤0.01% 2590
2025
Q3 		$17.3M Buy
13,971,557
+3,718,951
+36% +$4.43M ﹤0.01% 2519
2025
Q2 		$11.6M Buy
10,252,606
+49,277
+0.5% +$65.5K ﹤0.01% 2821
2025
Q1 		$14.9M Buy
10,203,329
+4,854,233
+91% +$9.15M ﹤0.01% 2367
2024
Q4 		$11.4M Buy
5,349,096
+309,502
+6% +$763K ﹤0.01% 2812
2024
Q3 		$14.1M Buy
5,039,594
+2,593,091
+106% +$6.91M ﹤0.01% 2454
2024
Q2 		$5.7M Sell
2,446,503
-666,722
-21% -$1.97M ﹤0.01% 3544
2024
Q1 		$13.9M Sell
3,113,225
-940,001
-23% -$3.92M ﹤0.01% 2489
2023
Q4 		$13M Sell
4,053,226
-62,404
-2% -$177K ﹤0.01% 2508
2023
Q3 		$13M Sell
4,115,630
-624,711
-13% -$2.74M ﹤0.01% 2354
2023
Q2 		$23.6M Buy
4,740,341
+391,838
+9% +$2.12M ﹤0.01% 1722
2023
Q1 		$21.5M Buy
4,348,503
+3,808,199
+705% +$24.4M ﹤0.01% 1846
2022
Q4 		$3.4M Sell
540,304
-352,551
-39% -$3.26M ﹤0.01% 4544
2022
Q3 		$9.64M Buy
892,855
+811,492
+997% +$11M ﹤0.01% 2828
2022
Q2 		$927K Sell
81,363
-2,534,748
-97% -$22.5M ﹤0.01% 7200
2022
Q1 		$23.8M Buy
2,616,111
+241,614
+10% +$2.52M ﹤0.01% 1785
2021
Q4 		$35.4M Buy
2,374,497
+2,064,988
+667% +$36.4M 0.01% 1463
2021
Q3 		$7.95M Sell
309,509
-101,301
-25% -$2.41M ﹤0.01% 3461
2021
Q2 		$10.7M Buy
410,810
+379,323
+1,205% +$10.8M ﹤0.01% 2971
2021
Q1 		$1.11M Sell
31,487
-272,366
-90% -$9.19M ﹤0.01% 7850
2020
Q4 		$7.67M Buy
303,853
+240,364
+379% +$7.83M ﹤0.01% 3008
2020
Q3 		$2.39M Sell
63,489
-33,851
-35% -$1.28M ﹤0.01% 4395
2020
Q2 		$4.17M Buy
97,340
+42,054
+76% +$1.52M ﹤0.01% 3341
2020
Q1 		$1.07M Sell
55,286
-960
-2% -$22.9K ﹤0.01% 5210
2019
Q4 		$1.46M Sell
56,246
-295,648
-84% -$8.14M ﹤0.01% 4919
2019
Q3 		$9.59M Sell
351,894
-91,683
-21% -$2.61M ﹤0.01% 2267
2019
Q2 		$11.9M Sell
443,577
-220,926
-33% -$6.16M 0.01% 1971
2019
Q1 		$19.2M Buy
664,503
+293,885
+79% +$8.53M 0.01% 1375
2018
Q4 		$9.98M Buy
+370,618
New +$9.85M 0.01% 1893

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Citadel Advisors's ALLO Position: Q1 2026 in Review

Citadel Advisors reduced its Allogene Therapeutics (ALLO) stake by 44% in Q1 2026, selling an estimated $10.7M and leaving 6,793,620 shares worth $16.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2564.

Citadel Advisors first reported a position in ALLO in Q4 2018 and has held it in 30 quarters since. The position peaked at $35.4M in Q4 2021. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Citadel Advisors held 6,793,620 shares of Allogene Therapeutics worth $16.6M as of Q1 2026.
  • Citadel Advisors sold 5,317,800 Allogene Therapeutics shares in Q1 2026, an estimated $10.7M.
  • Allogene Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2564 holding.
  • Citadel Advisors first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 30 quarters since.
  • Citadel Advisors's Allogene Therapeutics position peaked at $35.4M in Q4 2021.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.